PharPoint Research Strengthens European Capabilities
PharPoint Research, a U.S.-based contract research organization (CRO), today announced the expansion of their clinical trial management and consulting service capabilities into Europe. The extension provides PharPoint Research's global drug development clients greater access to increasingly meaningful markets and increases their reach across the European continent.
With rising interest in early phased research conducted outside of the United States, PharPoint’s expansion is the next step in their strategic plan for measured growth. “We have grown in response to market demand,” said Steve Young, Director of Integrated Clinical Strategies at PharPoint Research. “Our strength lies in our ability to respond to the direct needs of our Sponsors and to organize and manage efficient and effective clinical trials.” PharPoint has accomplished this feat by employing strategic global partnerships with European service providers of similar size that share the entrepreneurial spirit that upon which PharPoint was built.
Art Holmes, President and CEO at PharPoint, added “Our strategic alliances are key to our success. We partner with reputable organizations who share our vision and can provide the best possible services to our clients and vice versa. Despite the geographical location of a Sponsor, PharPoint has nurtured partnerships with service providers around the globe that can meet the needs of each clinical trial.”
PharPoint’s strategic global partnership approach builds upon the flexible clinical trial management model that PharPoint has used since their inception. Using this model, PharPoint is able to reduce clients’ costs by working with European partners to create a team of experts when they are needed. This allows for the efficient use of resources and reduction of lifecycle costs.
PharPoint looks forward to the enhanced clinical trial feasibility and access to a wider subject population this evolution provides to clients. For more information about PharPoint Research or how they can guide your next study, visit www.pharpoint.com or call + 1 919.433.2499.
About PharPoint Research
PharPoint Research, Inc. is a pharmaceutical development service provider specializing in clinical operations, data management and biostatistics. PharPoint’s approach is to work closely with clients to identify immediate, near-term and long-term requirements, then to create specific project teams and solutions designed to meet their goals. PharPoint prides itself on years of experience, superb repeat client rate, and the ability to consistently exceed the expectations of clients.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
AURAK22.7.2018 11:54 | pressemeddelelse
AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University
PHILIP-MORRIS-INTL21.7.2018 20:21 | pressemeddelelse
Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.
LOXAM20.7.2018 16:53 | pressemeddelelse
Loxam Announces a Conditional Agreement to Acquire UK Platforms
SCHLUMBERGER-LIMITED20.7.2018 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2018 Results
FL-H.I.G.-CAPITAL19.7.2018 21:52 | pressemeddelelse
H.I.G. Capital Announces the Sale of KidsFoundation
SIG-COMBIBLOC-GROUP19.7.2018 18:03 | pressemeddelelse
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum